Radiation therapy: Age-related macular degeneration

Developments in Ophthalmology

Volumn 52, Issue , 2013, Pages 75-84

  Medina Mendez, Carlos A ^a   Ehlers, Justis P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADJUVANT THERAPY; BRACHYTHERAPY; DRUG ANTAGONISM; EXUDATIVE MACULAR DEGENERATION; HUMAN; PROTON THERAPY; RETREATMENT; REVIEW;

ANGIOGENESIS INHIBITORS; BRACHYTHERAPY; HUMANS; PROTON THERAPY; RADIOTHERAPY, ADJUVANT; RETREATMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84884545053     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000351061     Document Type: Review

References (60)

1. Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, et al: The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol 2006; 17: 257-266.
2. Evans JR, Fletcher AE, Wormald RP: Causes of visual impairment in people aged 75 years and older in Britain: an add-on study to the MRC Trial of Assessment and Management of Older People in the Community. Br J Ophthalmol 2004; 88: 365-370.
3. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH: Ten-year incidence and progression of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 2002; 109: 1767-1779.
4. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564-572.
5. Ferris FL 3rd, Fine SL, Hyman L: Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640-1642.
6. Zarbin MA: Age-related macular degeneration: review of pathogenesis. Eur J Ophthalmol 1998; 8: 199-206.
7. Beatty S, Koh H, Phil M, Henson D, Boulton M: The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000; 45: 115-134.
8. Grossniklaus HE, Green WR: Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization. Submacular Surgery Trials Research Group. Arch Ophthalmol 1998; 116: 745-749.
9. Lopez PF, Grossniklaus HE, Lambert HM, Aaberg TM, Capone A Jr, Sternberg P Jr, et al: Pathologic features of surgically excised subretinal neovascular mem branes in age-related macular degeneration. Am J Ophthalmol 1991; 112: 647-656.
10. Yuan A, Kaiser PK: Emerging therapies for the treatment of neovascular age related macular degeneration. Semin Ophthalmol 2011; 26: 149-155.
11. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM: Racial differences in the prevalence of agerelated macular degeneration: the Baltimore Eye Survey. Ophthalmology 1999; 106: 1049-1055.
12. VanNewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, McCarty CA: The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000; 107: 1593-1600.
13. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP: Smoking and age-related macular degeneration: a review of association. Eye (Lond) 2005; 19: 935-944.
14. Klein R: Overview of progress in the epidemiology of age-related macular degeneration. Ophthalmic Epidemiol 2007; 14: 184-187.
15. Cruickshanks KJ, Klein R, Klein BE, Nondahl DM: Sunlight and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2001; 119: 246-250.
16. Delcourt C, Carriere I, Ponton-Sanchez A, Fourrey S, Lacroux A, Papoz L: Light exposure and the risk of age-related macular degeneration: the Pathologies Oculaires Liees a l'Age (POLA) study. Arch Ophthalmol 2001; 119: 1463-1468.
17. Couch SM, Bakri SJ: Review of combination therapies for neovascular age-related macular degeneration. Semin Ophthalmol 2011; 26: 114-120.
18. Macular Photocoagulation Study Group: Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991; 109: 1109-1114.
19. Hawkins BS, Bressler NM, Miskala PH, Bressler SB, Holekamp NM, Marsh MJ, et al: Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings. SST report No. 11. Ophthalmology 2004; 111: 1967-1980.
20. Bressler NM, Bressler SB, Childs AL, Haller JA, Hawkins BS, Lewis H, et al: Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings. SST report No. 13. Ophthalmology 2004; 111: 1993-2006.
21. Chen FK, Patel PJ, Uppal GS, Tufail A, Coffey PJ, Da Cruz L: Long-term outcomes following full macular translocation surgery in neovascular age-related macu lar degeneration. Br J Ophthalmol 2010; 94: 1337-1343.
22. Eandi CM, Giansanti F, Virgili G: Macular translocation for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2008; 4:CD006928.
23. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Arch Ophthalmol 1999; 117: 1329-1345.
24. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-560.
25. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
26. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Health Technol Assess 2008; 12:iii-iv, ix-201.
27. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
28. Nguyen QD, Heier J, Brown D, Ho A, Kaiser P, Vitti R, et al: Randomized, double-masked, active-controlled phase 3 trial of the efficacy and safety of intravitreal VEGF trap-eye in wet AMD: one-year results of the VIew-1 study IOVS. ARVO 2011, abstr 3073.
29. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al: Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119: 1399-1411.
30. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
31. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al: Intravitreal Aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-2548.
32. Chakravarthy U, Houston RF, Archer DB: Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study. Br J Ophthalmol 1993; 77: 265-273.
33. Petrarca R, Jackson TL: Radiation therapy for neovascular age-related macular degeneration. Clin Ophthalmol 2011; 5: 57-63.
34. Kirwan JF, Constable PH, Murdoch IE, Khaw PT: Beta irradiation: new uses for an old treatment: a review. Eye (Lond) 2003; 17: 207-215.
35. Trikha R, Morse LS, Zawadzki RJ, Werner JS, Park SS: Ten-year follow-up of eyes treated with stereotactic fractionated external beam radiation for neovascular age-related macular degeneration. Retina 2011; 31: 1303-1315.
36. Barnhard HJ: Supervoltage therapy comes of age: a report for the practicing physician. N Engl J Med 1958; 258: 275-277.
37. Chakravarthy U, MacKenzie G: External beam radiotherapy in exudative age-related macular degeneration: a pooled analysis of phase I data. Br J Radiol 2000; 73: 305-313.
38. Evans JR, Sivagnanavel V, Chong V: Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2010; 5:CD004004.
39. Moshfeghi DM, Kaiser PK, Gertner M: Stereotactic low-voltage X-ray irradiation for age-related macular degeneration. Br J Ophthalmol 2011; 95: 185-188.
40. Jampol LM: Oxygen therapy and intraocular oxygenation. Trans Am Ophthalmol Soc 1987; 85: 407-437.
41. Stefansson E, Landers MB 3rd, Wolbarsht ML: Increased retinal oxygen supply following pan-retinal photocoagulation and vitrectomy and lensectomy. Trans Am Ophthalmol Soc 1981; 79: 307-334.
42. Kim IK, Gragoudas ES: Radiation therapy for neovascular age-related macular degeneration revisited. Br J Ophthalmol 2009; 93: 279-280.
43. Senan S, Smit EF: Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 2007; 12: 465-477.
44. Sivagnanavel V, Evans JR, Ockrim Z, Chong V: Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2004; 4:CD004004.
45. Silva RA, Moshfeghi AA, Kaiser PK, Singh RP, Moshfeghi DM: Radiation treatment for age-related macular degeneration. Semin Ophthalmol 2011; 26: 121-130.
46. Jackson TL, Chakravarthy U, Kaiser PK, Slakter JS, Jan E, Bandello F, et al: Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration: 52-Week Safety and Efficacy Results of the INTREPID Study. Ophthalmology, in press.
47. Jackson TL: INTREPID data and its significance. 12th Euretina Congress, Milan, 2012.
48. Finger PT, Berson A, Sherr D, Riley R, Balkin RA, Bosworth JL: Radiation therapy for subretinal neovascularization. Ophthalmology 1996; 103: 878-889.
49. Finger PT, Berson A, Ng T, Szechter A: Ophthalmic plaque radiotherapy for age-related macular degeneration associated with subretinal neovascularization. Am J Ophthalmol 1999; 127: 170-177.
50. Avila MP, Farah ME, Santos A, Carla L, Fuji G, Rossi J, et al: Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina 2012; 32: 10-18.
51. Dugel P: CABERNET: for treatment of naive neovascular macular degeneration. Angiogenesis, Miami, 2012.
52. Dugel PU, Bebchuk JD, Nau J, Reichel E, Singer M, Barak A, et al: Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology 2013; 120: 317-327.
53. Guyer DR, Mukai S, Egan KM, Seddon JM, Walsh SM, Gragoudas ES: Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology 1992; 99: 1278-1285.
54. Flaxel CJ: Use of radiation in the treatment of age-related macular degeneration. Ophthalmol Clin North Am 2002; 15: 437-444, v.
55. Hoehn ME, Irshad F, Kerr NC, Wilson MW: Outcomes after cataract extraction in young children with radiation-induced cataracts and retinoblastoma. J AAPOS 2010; 14: 232-234.
56. Cogan DG, Donaldson DD, Reese AB: Clinical and pathological characteristics of radiation cataract. AMA Arch Ophthalmol 1952; 47: 55-70.
57. Archer DB, Gardiner TA: Ionizing radiation and the retina. Curr Opin Ophthalmol 1994; 5: 59-65.
58. Archer DB: Doyne Lecture. Responses of retinal and choroidal vessels to ionising radiation. Eye (Lond) 1993; 7: 1-13.
59. Rodel F, Keilholz L, Herrmann M, Sauer R, Hildebrandt G: Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy. Int J Radiat Biol 2007; 83: 357-366.
60. Wachsberger P, Burd R, Dicker AP: Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003; 9: 1957-1971.